What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).”In the company’s words, NCT06488313 on ClinicalTrials.gov
- Tested for
- OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD
- Main trialPhase 2
- “Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.”In the company’s words, NCT06488313 on ClinicalTrials.gov
Other drugs for OTC Deficiency
- DTX301Ultragenyx Pharmaceutical Inc · Phase 3
- KRRO-121Korro Bio, Inc. · Phase 1/2
- CMP-CPS-001CAMP4 Therapeutics Corporation · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 1 Jun 2026 | A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD | |
| Phase 2Terminated | 31 Oct 2024 | Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 | |
| Phase 1Completed | 9 Dec 2020 | Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects | |
| Phase 1Completed | 30 Aug 2023 | Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026